波形蛋白（VIM）和转移相关蛋白 1（MTA1）在喉鳞状细胞癌中的表达与患者的预后结果相关。

Expression of vimentin (VIM) and metastasis-associated 1 (MTA1) protein in laryngeal squamous cell carcinoma are associated with prognostic outcome of patients.

机构信息

First Department of Otolaryngology, Athens General Hospital "Hippokration", Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Am J Otolaryngol. 2019 Jul-Aug;40(4):487-493. doi: 10.1016/j.amjoto.2019.04.002. Epub 2019 Apr 3.

DOI:10.1016/j.amjoto.2019.04.002

PMID:30979652

Abstract

PURPOSE

Laryngeal squamous cell carcinoma (LSCC), a common type of head and neck cancer, is associated with high rates of metastasis and recurrence. In this study, we investigated the potential combinatorial prognostic value of NOTCH1, Vimentin (VIM), and Metastasis-associated 1 (MTA1) protein in LSCC, using immunohistochemistry.

MATERIALS AND METHODS

Tissue specimens from 69 patients with LSCC were immunohistochemically evaluated for the protein expression of NOTCH1, VIM, and MTA1. Then, biostatistical analysis was performed, in order to assess the prognostic value of the expression of each one of these proteins.

RESULTS

NOTCH1 expression status was not a significant prognosticator in LSCC, as shown in Kaplan-Meier survival analysis. On the contrary, both VIM and MTA1 seem to have an important prognostic potential, independently of TNM staging and histological grade of the tumor. In fact, positive VIM expression was shown to predict patients' relapse and poor outcome regarding patients' overall survival, in contrast with MTA1, the positive expression of which predicts higher disease-free survival (DFS) and overall survival (OS) rates in LSCC.

CONCLUSIONS

VIM and MTA1 constitute potential tumor biomarkers in LSCC and could be integrated into a multiparametric prognostic model. Undoubtedly, their prognostic value needs further validation in larger cohorts of LSCC patients.

摘要

目的

喉鳞状细胞癌（LSCC）是一种常见的头颈部癌症，其转移和复发率较高。在这项研究中，我们通过免疫组织化学法研究了 NOTCH1、波形蛋白（VIM）和转移相关蛋白 1（MTA1）蛋白在 LSCC 中的潜在联合预后价值。

材料与方法

对 69 例 LSCC 患者的组织标本进行 NOTCH1、VIM 和 MTA1 蛋白的免疫组织化学评估。然后，进行生物统计学分析，以评估这些蛋白表达的预后价值。

结果

NOTCH1 表达状态在 LSCC 中不是一个显著的预后预测因子，如 Kaplan-Meier 生存分析所示。相反，VIM 和 MTA1 似乎都具有独立于 TNM 分期和肿瘤组织学分级的重要预后潜力。事实上，阳性 VIM 表达预示着患者的复发和总体生存率不良，而 MTA1 阳性表达则预示着 LSCC 更高的无病生存率（DFS）和总生存率（OS）。